MYCOPHENOLATE MOFETIL IN ASSOCIATION WITH PEG-IFN-ALPHA

摘要

The use of therapeutically effective amount of IFN- alpha or PEG-IFN- alpha in association with a therapeutically effective amount of a pharmaceutically acceptable salt or prodrug of mycophenolic acid for the manufacture of medicaments for treating liver diseases patients. The components are administered over a period of time at least sufficient to reduce the amount of HCV-RNA present in the peripheral blood of said patient to less than 100 copies/ml at 24 weeks after the end of treatment.